๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Measurement of prostate-specific membrane antigen in the serum with a new antibody

โœ Scribed by Murphy, G. P.; Tino, W. T.; Holmes, E. H.; Boynton, A. L.; Erickson, S. J.; Bowes, V. A.; Barren, R. J.; Tjoa, B. A.; Misrock, S. L.; Ragde, H.; Kenny, G. M.


Publisher
John Wiley and Sons
Year
1996
Tongue
English
Weight
571 KB
Volume
28
Category
Article
ISSN
0270-4137

No coin nor oath required. For personal study only.

โœฆ Synopsis


Work to date has identified prostate-specific membrane antigen (PSMA) as a membrane-bound glycoprotein with high specificity for prostatic epithelial cells. PSMA reacts with the monoclonal antibody 7Ell.C5, which is present in serum, seminal fluid, and prostatic epithelial cells, and is increased in its expression in the presence of a hormone refractory state associated with prostatic cancer. This report confirms these results and further documents the presence of the monoclonal antibody 3F5.4G6, which reacts with the extracellular domain of PSMA. This region of PSMA is also an element present in a truncated version of the protein, so-called EM'. Immune precipitation with either 7Ell.C5 or 3F5.4G6 yields an isolated protein species that are reactive with the reciprocal antibody in Western blot analysis. Thus, 3F5.4G6 recognizes the same PSMA protein as does 7Ell.C5, but at different epitopes on essentially opposite ends of the molecule. These two antibodies are well suited for use in a sandwich immunoassay, either one as a capture or detection antibody. Current work on this is underway.

This report also confirms that 7Ell.C5 Western blots for PSMA are negative with normal human brain tissue. The monoclonal antibody 9H10 does not react with 3F5.4G6 or with 7Ell.C5 in studies conducted herein. Moreover, 3F5.4G6 reacts with PSMA found in the LNCaP cell line, but not DU-145 or PC3, which lack PSMA.


๐Ÿ“œ SIMILAR VOLUMES


Comparison of serum prostate specific me
โœ Thomas H. Douglas; Ted O. Morgan; David G. McLeod; Judd W. Moul; Gerald P. Murph ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 92 KB ๐Ÿ‘ 1 views

ated with higher pathologic stage and grade in patients undergoing radical prostatectomy (RP). In earlier studies, serum prostate specific membrane antigen (PSMA)

Prostate specific antigen predominantly
โœ Hans Lilja; Abraham T. K. Cockett; Per-Anders Abrahamsson ๐Ÿ“‚ Article ๐Ÿ“… 1992 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 471 KB ๐Ÿ‘ 2 views

Background. Prostate specific antigen (PSA) is a zymogen of a 33-kilodalton (kD) serine proteinase with extensive similarity to glandular kallikreins. The mechanism responsible for converting the zymogen into active proteinase has not been defined, but active PSA may be irreversibly inactivated in v

Evaluation and comparison of two new pro
โœ Gerald P. Murphy; Robert J. Barren; Sheila J. Erickson; Victoria A. Bowes; Rober ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 816 KB

## BACKGROUND. Two new prostate cancer markers, free-prostate specific antigen (f-PSA) and prostate specific membrane antigen (PSMA) were recently introduced. This report summarizes a prospective two-year multicenter test of their diagnostic or prognostic capabilities. Total PSA was also measured.

Radiotherapy for localized prostate carc
โœ Juanita M. Crook; Yasir A. Bahadur; R. Gregory Bociek; Gad A. Perry; Susan J. Ro ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 127 KB ๐Ÿ‘ 2 views

## Background: The objective of this study was to correlate the failure pattern of localized prostate carcinoma after radiotherapy (rt) with pretreatment (pretx) psa and post-rt nadir psa, using systematic biopsies and serum psa in the assessment of outcome. ## Methods: From january 1990 to febru

Location of prostate-specific membrane a
โœ Troyer, John K.; Beckett, Mary Lou; Wright, George L. ๐Ÿ“‚ Article ๐Ÿ“… 1997 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 836 KB

## Background: Prostate-specific membrane antigen (psma) is a novel prostate biomarker overexpressed in poorly differentiated and metastatic prostate carcinomas and apparently upregulated following hormone-ablation therapy. psma appears to be a satisfactory target for antibody-directed imaging of p